Last reviewed · How we verify
TTI-0102: cysteamine-pantetheine disulfide — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
TTI-0102: cysteamine-pantetheine disulfide (TTI-0102: cysteamine-pantetheine disulfide) — Thiogenesis Therapeutics, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| TTI-0102: cysteamine-pantetheine disulfide TARGET | TTI-0102: cysteamine-pantetheine disulfide | Thiogenesis Therapeutics, Inc. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- TTI-0102: cysteamine-pantetheine disulfide CI watch — RSS
- TTI-0102: cysteamine-pantetheine disulfide CI watch — Atom
- TTI-0102: cysteamine-pantetheine disulfide CI watch — JSON
- TTI-0102: cysteamine-pantetheine disulfide alone — RSS
Cite this brief
Drug Landscape (2026). TTI-0102: cysteamine-pantetheine disulfide — Competitive Intelligence Brief. https://druglandscape.com/ci/tti-0102-cysteamine-pantetheine-disulfide. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab